Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
April 27, 2023 at 12:40 pm
Share
Honz Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was CNY 174.6 million compared to CNY 109.95 million a year ago. Revenue was CNY 174.6 million compared to CNY 109.95 million a year ago.
Net income was CNY 15.41 million compared to net loss of CNY 46.24 million a year ago. Basic earnings per share from continuing operations was CNY 0.0343 compared to basic loss per share from continuing operations of CNY 0.1028 a year ago. Diluted earnings per share from continuing operations was CNY 0.0343 compared to diluted loss per share from continuing operations of CNY 0.1028 a year ago.
HONZ PHARMACEUTICAL CO., LTD., formerly HAINAN HONZ PHARMACEUTICAL CO., LTD., is principally engaged in the research, development, production and distribution of drugs for children. The Company provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The Company's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.